Andreoni M - Search Results

1

Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.

d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, Lazzarin A, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A; ICONA Foundation Cohort. d'Arminio Monforte A, et al. Among authors: andreoni m. Antivir Ther. 2014;19(3):319-24. doi: 10.3851/IMP2687. Epub 2013 Sep 13. Antivir Ther. 2014. PMID: 24036891

2

A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.

Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K. Vella S, et al. Among authors: andreoni m. Antivir Ther. 1996 Aug;1(3):129-40. Antivir Ther. 1996. PMID: 11322246 Clinical Trial.

3

Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.

Carosi G, Castelli F, Suter F, Maggiolo F, Orani AM, Pan A, Andreoni M, Vigevani GM, Maserati R, Mazzotta F, Tinelli C; MATER Study Group. Carosi G, et al. Among authors: andreoni m. HIV Clin Trials. 2001 Sep-Oct;2(5):399-407. doi: 10.1310/5xcl-5xe9-jafk-xk7y. HIV Clin Trials. 2001. PMID: 11673814 Clinical Trial.

4

Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy.

Malnati M, Broccolo F, Nozza S, Sarmati L, Ghezzi S, Locatelli G, Delfanti F, Capiluppi B, Careddu A, Andreoni M, Monini P, Poli G, Lazzarin A, Lusso P, Tambussi G. Malnati M, et al. Among authors: andreoni m. Blood. 2002 Sep 1;100(5):1575-8. Blood. 2002. PMID: 12176873 Free article.

5

No protective effect of acyclovir on HIV disease progression in a cohort of HSV-2-HIV-infected individuals.

Suligoi B, Dorrucci M, Volpi A, Andreoni M, Rezza G; Italian Seroconversion Study. Suligoi B, et al. Among authors: andreoni m. Antivir Ther. 2002 Dec;7(4):289-91. Antivir Ther. 2002. PMID: 12553484

6

Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.

Nicastri E, Chiesi A, Angeletti C, Sarmati L, Palmisano L, Geraci A, Andreoni M, Vella S; Italian Antiretroviral Treatment Group (IATG). Nicastri E, et al. Among authors: andreoni m. J Med Virol. 2005 Jun;76(2):153-60. doi: 10.1002/jmv.20352. J Med Virol. 2005. PMID: 15834865

7

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V. Carosi G, et al. Among authors: andreoni m. J Antimicrob Chemother. 2006 Jun;57(6):1055-64. doi: 10.1093/jac/dkl113. Epub 2006 Apr 10. J Antimicrob Chemother. 2006. PMID: 16606637

8

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G. Antinori A, et al. Among authors: andreoni m. Antivir Ther. 2006;11(2):233-43. Antivir Ther. 2006. PMID: 16640104

9

Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.

Antinori A, Trotta MP, Lorenzini P, Torti C, Gianotti N, Maggiolo F, Ceccherini-Silberstein F, Nasto P, Castagna A, De Luca A, Mussini C, Andreoni M, Perno CF; GNOMO Study Group. Antinori A, et al. Among authors: andreoni m. Antivir Ther. 2007;12(8):1175-83. Antivir Ther. 2007. PMID: 18240858

10

HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.

Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, Andreotti M, Buonomini A, Pirillo FM, Narciso P, Bellagamba R, Vullo V, Montano M, Di Perri G, Andreoni M. Nicastri E, et al. Among authors: andreoni m. Curr HIV Res. 2008 May;6(3):261-6. doi: 10.2174/157016208784325010. Curr HIV Res. 2008. PMID: 18473790

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

539 results

Search Page